-+ 0.00%
-+ 0.00%
-+ 0.00%

Rigel Q2 FY26 net income falls to $17.3 million; revenue drops to $78.7 million

PUBT·08/04/2026 20:08:17
Listen to the news
Rigel Q2 FY26 net income falls to $17.3 million; revenue drops to $78.7 million
  • Rigel posted Q2 2026 revenue of USD 78.7 million; net income fell to USD 17.3 million from USD 59.6 million a year earlier.
  • Net product sales rose 14% to USD 67.0 million, led by TAVALISSE up 18% to USD 47.4 million.
  • Total costs and expenses climbed to USD 55.1 million from USD 40.6 million, on higher personnel, cost of product sales, and R&D.
  • In-licensed VEPPANU (vepdegestrant) under a global deal effective June 11; U.S. commercial availability expected in mid-August.
  • Raised 2026 revenue outlook to about USD 285 million-USD 295 million, excluding VEPPANU; still expects positive full-year net income.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rigel Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF18516) on August 04, 2026, and is solely responsible for the information contained therein.